Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up [Seeking Alpha]
MaxCyte, Inc. (MXCT)
Company Research
Source: Seeking Alpha
Play 7min Summary MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA approval of CASGVEY validates MaxCyte's platform, with potential multi-billion dollar opportunities and significant future revenue. With 29 active SPLs, MaxCyte's NPV could be $2.4 billion, suggesting a strong upside potential and a reasonable margin of safety. Images By Tang Ming Tung I've been following MaxCyte, Inc. MXCT ) for years now, since they IPO'ed on the London exchange ( LSE: MXCT ). About a year ago, I wrote about MaxCyte's unique business model This article was written by Jonquil Capital Follower s Follow Jonquil Capital is a private investor, investment analyst, and writer from Smyrna, Georgia - the Jonquil city.Hopefully, by putting some words down in a pa
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte Announces Retirement of Board Member Art MandellGlobeNewswire
- MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- MaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceGlobeNewswire
- This MaxCyte Insider Increased Their Holding In The Last Year [Yahoo! Finance]Yahoo! Finance
- MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsGlobeNewswire
MXCT
Earnings
- 11/6/24 - Beat
MXCT
Sec Filings
- 12/26/24 - Form 144
- 12/10/24 - Form 4
- 12/9/24 - Form 8-K
- MXCT's page on the SEC website